DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biopharmaceutical company using
its proprietary RADR® artificial intelligence ("A.I.")
platform to transform the cost, pace, and timeline of oncology drug
discovery and development, announced today that it has entered into
a research and development collaboration with Actuate Therapeutics.
The collaboration will focus on leveraging the RADR®
machine learning technology, large-scale oncology datasets, and the
A.I. platform to accelerate key aspects of Actuate's 9-ING-41 drug
candidate, a best-in-class GSK-3β inhibitor in active development
in multiple Phase 2 clinical trials, including for pancreatic
cancer. The collaboration is expected to start immediately and will
potentially generate novel intellectual property that will be
jointly owned by the companies.
![Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma) Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma)](https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg)
Daniel Schmitt, President
and Chief Executive Officer of Actuate Therapeutics, commented,
"Accelerating the development of 9-ING-41 by leveraging the latest
techniques in machine learning and genomics has the potential to
aid in bringing our life altering therapies to patients faster and
with a greater degree of precision. We are committed to leveraging
the latest advances in biomarker driven medicine and technology to
advance our drug candidates in the most promising sub-types of
cancer and in patients who may have the highest likelihood to
benefit from our therapy." In a study published on February 23, 2021 in the journal Cancer Medicine,
Dr. Jayson Parker from the
University of Toronto and his
co-authors provided systematic statistical evidence that biomarkers
when used in patient stratification and monitoring in oncology
clinical trials improve the likelihood of drug regulatory approvals
by a factor of five.
Lantern Pharma recently announced that the
RADR® platform had surpassed 4.6 billion datapoints
and had advanced certain aspects of automation and machine learning
as a result of the latest development campaign. The latest
development campaign was aimed at improving the predictive power of
the biomarker signatures created by RADR® and the
ability to potentially impact drug development in a broader range
of solid tumor subtypes. Lantern expects that RADR® will
surpass 10 billion curated and tagged oncology datapoints over the
next 12 months, which has the potential to make the platform even
more useful across a broader range of cancer development and drug
development or rescue programs.
Panna Sharma, CEO and
President of Lantern Pharma, stated, "Companies like Actuate that
are adopting methods that are at the forefront of this new era of
data and A.I. guided drug development have the potential to conduct
future clinical trials with biomarker signatures that have been
generated at a fraction of the cost of traditional techniques.
Using highly scalable machine-learning methods to guide drug
development can potentially yield new biological insights, while
also increasing response rates and improving outcomes in clinical
trials."
Under the terms of the collaboration, Lantern Pharma will
receive upfront equity in Actuate Therapeutics subject to meeting
certain conditions of the collaboration, as well as development
milestones in the form of additional equity if results from the
collaboration are utilized in future development efforts. No
further financial details were disclosed.
Contact
Marek Ciszewski, J.D.
Director, Investor Relations
628-777-3167
ir@lanternpharma.com
About Actuate Therapeutics
Actuate Therapeutics, Inc. is a clinical stage pharmaceutical
company focused on the development and commercialization of novel
therapeutics for cancers and inflammatory diseases. For additional information, please visit
the company's website at http://www.actuatetherapeutics.com.
About Lantern Pharma
Lantern Pharma (Nasdaq: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® A.I. platform and machine learning to
discover biomarker signatures that identify patients most likely to
respond to its pipeline of genomically-targeted therapeutics.
Lantern is currently developing four drug candidates and an ADC
program across seven disclosed tumor targets, including two phase 2
programs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, Lantern's approach represents the potential to
deliver best-in-class outcomes. More information is available at:
www.lanternpharma.com and Twitter @lanternpharma.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; our strategic plans to advance our
collaboration with Actuate Therapeutics; the potential advantages
of our RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
the utilization of our RADR® platform to streamline the
drug development process; and our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate. Any statements that are not statements
of historical fact (including, without limitation, statements that
use words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "objective'" "aim,"
"should," "will," "would," or the negative of these words or other
similar expressions) should be considered forward-looking
statements. There are a number of important factors that could
cause our actual results to differ materially from those indicated
by the forward-looking statements, such as (i) the impact of the
COVID-19 pandemic, (ii) the risk that our collaboration with
Actuate Therapeutics may not be successful and may not yield
meaningful results, (iii) the risk that no drug product
based on our proprietary RADR® A.I. platform has
received FDA marketing approval or otherwise been incorporated into
a commercial product, (iv) the risk that none of our product
candidates has received FDA marketing approval, and we may not be
able to successfully initiate, conduct, or conclude clinical
testing for or obtain marketing approval for our product
candidates, and (v) those other factors set forth in the Risk
Factors section in our Annual Report on Form 10-K for the year
ended December 31, 2020, filed with
the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report
on Form 10-K for the year ended December 31,
2020 under the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov. Given
these risks and uncertainties, we can give no assurances that our
forward-looking statements will prove to be accurate, or that any
other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-and-actuate-therapeutics-announce-research--development-collaboration-leveraging-lanterns-artificial-intelligence-platform-301282027.html
SOURCE Lantern Pharma